Cabio Biotech (Wuhan) (688089.SH) plans to acquire 65% equity of Ouyi Biotech. Trading of the company's stocks will resume on November 12th.

Cabio Biotech (Wuhan) (688089.SH) announced that it plans to acquire 65% equity of Shanghai Ouyi Biomedical Technology Co., Ltd. (referred to as Ouyi Bio) from 14 trading parties including Wang Shuwei, Dong Dong, Xiao Yunping, Wang Xiuping, Jin Chao, Shi Xianjun, Shanghai Fanye, Ningbo Ruio, Ningbo Ourun, Sinopharm Phase II, Nantong Dongzheng, Suzhou Dingshi, Shanghai Biology, and Shanghai Shengqi through issuing shares and cash payment, and raise supporting funds. The company's stock will resume trading on November 12, 2024. The target company is based on multi-omics technology and big data analysis technology, providing multi-level multi-omics analysis technology services for research applications in life science, medicine, food, cosmetics and other fields, as well as independently developing a series of genetic disease diagnostic reagent products. With an innovative-driven research and development strategy, the target company has successfully built a high-quality brand of "innovative multi-omics" by achieving multi-omics integration around the central idea. During the reporting period, it has established deep cooperative relationships with over 2,000 universities, research institutes, hospitals, and enterprises. Through this transaction, the company and the target company can empower and complement each other with their own business and technological advantages, forming synergies in various aspects such as biotechnology, data information, customer resources, and market channels. At the same time, the company's main business will further extend to the field of scientific and technological services, creating an integrated industry service platform of "technical services + innovative functional polymer exploration + product output", achieving synergies between products and services, and providing complete solutions for customers. Leveraging their core technological capabilities and specific advantages, the company and the target company will effectively integrate resources in technology, information, market, and products, strengthen the company's technological research and development capabilities and customer service capabilities, improve production efficiency, enhance the overall scale of the company, and strengthen market competitiveness.